February 2017 – Wuhan YZY Biophama's another core technology patent is granted by the United States Patent Office. This invention patent describes asymmetric structure of bispecific antibodies targeting both tumor antigen and antigen on immune cell. Awarding of the patent is a great milestone for the company’s bispecific antibody technology platform. The patent will help the company further strengthens the IP protection for drug candidates of its pipeline.
Wuhan YZY Biopharma's bispecific antibody technology platform focuses on developing innovative drugs for cancer. Two bispecific antibody candidates have been in the stage of IND application reviewing. The R& D team of Wuhan YZY biopharma devotes to continuous innovative research and has established a rich pipeline with drug candidates at different development stages. The senior management of the company attaches grea timportance to IP protection throughout the drug research and development process. The company not only has a great number of patents, but has established synergistic IP strategies. The company has applied for more than 20 high-quality patents. In the near future, Wuhan YZY Biopharma will develop a series of therapeutic drugs to meet needs of patients, markets and corporate development.